- Home
- JBI vs XERS Comparison
JBI vs XERS Comparison
Compare JBI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBI | XERS |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.0M | 1.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JBI | XERS |
|---|---|---|
| Price | $7.07 | $6.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $10.17 | ★ $10.43 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $44.77 |
| Revenue Next Year | $1.58 | $27.72 |
| P/E Ratio | $21.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.73 | $3.56 |
| 52 Week High | $10.80 | $10.08 |
Technical Indicators
Market Signals| Indicator | JBI | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 43.23 |
| Support Level | $6.57 | $6.78 |
| Resistance Level | $7.48 | $7.10 |
| Average True Range (ATR) | 0.27 | 0.30 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 54.10 | 20.37 |
Price Performance
Historical ComparisonAbout JBI Janus International Group Inc.
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).